MediciNova, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 96   

Articles published

MNOV 4.00 +0.06 (1.52%)
price chart
MediciNova Inc. (MNOV) Leaped To A New High On FDA Fast Track Designation
MediciNova Inc. (MNOV: Quote) announced Thursday morning that it has received Fast Track designation from the FDA for MN-001, for the treatment of patients with nonalcoholic steatohepatitis with fibrosis.
Biotech Stocks Attracting Some Extra Attention - MediciNova (MNOV), AVEO ...  Wall Street Observer
MediciNova Inc. (MNOV) Has Surged To A New High On FDA Fast Track ...
MediciNova Inc. (MNOV: Quote) announced Thursday morning that it has received Fast Track designation from the FDA for MN-001, for the treatment of patients with nonalcoholic steatohepatitis with fibrosis.
Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova ...  GlobeNewswire (press release)
Today's Stocks: MediciNova Inc. (NASDAQ:MNOV), Cliffs Natural Resources Inc ...
MediciNova Inc. (NASDAQ:MNOV) belongs to Healthcare sector. Its weekly performance is 4.17%. On last trading day company shares ended up $4.00.
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) Hits New High Range With ...
MediciNova Inc. (NASDAQ:MNOV) [Trend Analysis] and JASDAQ Market of the Tokyo Stock Exchange, reported that the Tokyo Stock Exchange (TSE) has released a new rule affecting the trading of dual-listed stocks on the Tokyo Stock Exchange, including ...
Stocks clocking 52-week highs: Momenta Pharmaceuticals, Inc. (NASDAQ ...  Wall Street Observer
MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN ...
Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased with the findings from the interim safety analysis, as we may now continue with the trial as planned.
Medicinova (MNOV) Reports MN-166 Interim Safety Data Presented at AAN  StreetInsider.com
MediciNova to Initiate Clinical Trial of MN-166 (ibudilast) in ALS
LA JOLLA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced ...
Related articles »  
MediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS
LA JOLLA, Calif., Feb. 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced ...
MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in ...
LA JOLLA, Calif., Feb. 10, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced ...
MediciNova Confirms FDA Approval of Phase 2 Trial of MN-001 for Treatment of ...  Stock Transcript
Hot Biotech Stocks: Athersys, Inc. (NASDAQ:ATHX), MediciNova Inc. (NASDAQ ...
Athersys, Inc. (NASDAQ:ATHX) belongs to Healthcare sector. Its weekly performance is -27.33%. On last trading day company shares ended up $2.18.
Hot Stocks Alert:Athersys, Inc. (NASDAQ:ATHX), MediciNova, Inc. (NASDAQ ...  Market News Call
MediciNova's MN-001 (tipelukast) NASH with Advanced Fibrosis Abstract ...
LA JOLLA, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced ...